This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations of Xingxun Zhu in Cancer Treatment
Introduction
Xingxun Zhu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative cancer treatments. His work focuses on the use of SMAC mimetics as IAP inhibitors, which are crucial in the fight against various types of cancer.
Latest Patents
Xingxun Zhu holds 1 patent for his invention titled "SMAC mimetics used as IAP inhibitors and use thereof." This patent discloses a class of SMAC mimetics that serve as IAP inhibitors. The compounds, as shown in formula (I), include isomers and pharmaceutically acceptable salts. These IAP inhibitors are particularly aimed at treating cancers, with a focus on breast cancer.
Career Highlights
Xingxun Zhu is affiliated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the pharmaceutical industry, contributing to innovative solutions for cancer treatment.
Collaborations
Xingxun Zhu collaborates with notable colleagues, including Yingchun Liu and Zhaobing Xu. Their combined expertise enhances the research and development efforts within their organization.
Conclusion
Xingxun Zhu's innovative work in developing SMAC mimetics as IAP inhibitors represents a significant advancement in cancer treatment. His contributions are vital in the ongoing battle against cancer, particularly breast cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile